204 related articles for article (PubMed ID: 31664190)
1. Polymorphisms of NF-κB pathway genes influence adverse drug reactions of gefitinib in NSCLC patients.
Xin S; Zhao Y; Wang C; Huang Y; Zhuang W; Ma Y; Huang M; Xu X; Wang X; Zhang L
Pharmacogenomics J; 2020 Apr; 20(2):285-293. PubMed ID: 31664190
[TBL] [Abstract][Full Text] [Related]
2. Association of polymorphisms in AKT1 and EGFR with clinical outcome and toxicity in non-small cell lung cancer patients treated with gefitinib.
Giovannetti E; Zucali PA; Peters GJ; Cortesi F; D'Incecco A; Smit EF; Falcone A; Burgers JA; Santoro A; Danesi R; Giaccone G; Tibaldi C
Mol Cancer Ther; 2010 Mar; 9(3):581-93. PubMed ID: 20159991
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of gefitinib systemic exposure in EGFR-mutated non-small cell lung cancer patients with gefitinib-induced severe hepatotoxicity.
Kawamura T; Imamura CK; Kenmotsu H; Taira T; Omori S; Nakashima K; Wakuda K; Ono A; Naito T; Murakami H; Mushiroda T; Takahashi T; Tanigawara Y
Cancer Chemother Pharmacol; 2020 Mar; 85(3):605-614. PubMed ID: 32040702
[TBL] [Abstract][Full Text] [Related]
4. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
5. Determinants of Gefitinib toxicity in advanced non-small cell lung cancer (NSCLC): a pharmacogenomic study of metabolic enzymes and transporters.
Ma Y; Xin S; Huang M; Yang Y; Zhu C; Zhao H; Zhang Y; Chen L; Zhao Y; Li J; Zhuang W; Zhu X; Zhang L; Wang X
Pharmacogenomics J; 2017 Jul; 17(4):325-330. PubMed ID: 27089937
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
Nishio M; Kato T; Niho S; Yamamoto N; Takahashi T; Nogami N; Kaneda H; Fujita Y; Wilner K; Yoshida M; Isozaki M; Wada S; Tsuji F; Nakagawa K
Cancer Sci; 2020 May; 111(5):1724-1738. PubMed ID: 32159882
[TBL] [Abstract][Full Text] [Related]
7. Association of genetic polymorphisms of CYP3A4 and CYP2D6 with gefitinib-induced toxicities.
Kwok WC; Lam DCL; Ip MSM; Tam TCC; Ho JCM
Anticancer Drugs; 2022 Nov; 33(10):1139-1144. PubMed ID: 35946566
[TBL] [Abstract][Full Text] [Related]
8. RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation.
Cho JH; You YM; Yeom YI; Lee DC; Kim BK; Won M; Cho BC; Kang M; Park S; Yang SJ; Kim JS; Kim JA; Park KC
Cell Death Dis; 2018 May; 9(6):587. PubMed ID: 29789542
[TBL] [Abstract][Full Text] [Related]
9. Induction of Acquired Resistance towards EGFR Inhibitor Gefitinib in a Patient-Derived Xenograft Model of Non-Small Cell Lung Cancer and Subsequent Molecular Characterization.
Schueler J; Tschuch C; Klingner K; Bug D; Peille AL; de Koning L; Oswald E; Klett H; Sommergruber W
Cells; 2019 Jul; 8(7):. PubMed ID: 31323891
[TBL] [Abstract][Full Text] [Related]
10. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Akasaka K; Kaburagi T; Yasuda S; Ohmori K; Abe K; Sagara H; Ueda Y; Nagao K; Imura J; Imai Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):691-8. PubMed ID: 20035425
[TBL] [Abstract][Full Text] [Related]
11. Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients.
Xin S; Fang W; Li J; Li D; Wang C; Huang Q; Huang M; Zhuang W; Wang X; Chen L
J Cancer Res Clin Oncol; 2021 Mar; 147(3):725-737. PubMed ID: 33387041
[TBL] [Abstract][Full Text] [Related]
12. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
[TBL] [Abstract][Full Text] [Related]
13. Liver X receptors agonist GW3965 re-sensitizes gefitinib-resistant human non-small cell lung cancer cell to gefitinib treatment by inhibiting NF-κB in vitro.
Hu Y; Zang J; Cao H; Wu Y; Yan D; Qin X; Zhou L; Fan F; Ni J; Xu X; Sha H; Liu S; Yu S; Wang Z; Ma R; Wu J; Feng J
Oncotarget; 2017 Feb; 8(9):15802-15814. PubMed ID: 28178657
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetics and Adverse Events of Erlotinib in Japanese Patients with Non-small-cell Lung Cancer: Impact of Genetic Polymorphisms in Metabolizing Enzymes and Transporters.
Endo-Tsukude C; Sasaki JI; Saeki S; Iwamoto N; Inaba M; Ushijima S; Kishi H; Fujii S; Semba H; Kashiwabara K; Tsubata Y; Hayashi M; Kai Y; Saito H; Isobe T; Kohrogi H; Hamada A
Biol Pharm Bull; 2018; 41(1):47-56. PubMed ID: 29311482
[TBL] [Abstract][Full Text] [Related]
15. First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression.
Schuler M; Tan EH; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; Yang JC; Lee KH; Lu S; Shi Y; Kim SW; Laskin J; Kim DW; Arvis CD; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K
J Cancer Res Clin Oncol; 2019 Jun; 145(6):1569-1579. PubMed ID: 30783814
[TBL] [Abstract][Full Text] [Related]
16. The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.
Powrózek T; Mlak R; Krawczyk P; Homa I; Ciesielka M; Kozioł P; Prendecka M; Milanowski J; Małecka-Massalska T
Clin Transl Oncol; 2016 Feb; 18(2):125-31. PubMed ID: 26193985
[TBL] [Abstract][Full Text] [Related]
17. Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
Hirsch FR; Sequist LV; Gore I; Mooradian M; Simon G; Croft EF; DeVincenzo D; Munley J; Stein D; Freivogel K; Sifakis F; Bunn PA
Cancer; 2018 Jun; 124(11):2407-2414. PubMed ID: 29579334
[TBL] [Abstract][Full Text] [Related]
18. Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after treatment with gefitinib.
Park S; Park S; Choi H; Park JY; Lim HS; Park MJ; Kim SY
Korean J Intern Med; 2018 Jan; 33(1):211-213. PubMed ID: 27889954
[No Abstract] [Full Text] [Related]
19. Short-hairpin RNA library: identification of therapeutic partners for gefitinib-resistant non-small cell lung cancer.
Sudo M; Mori S; Madan V; Yang H; Leong G; Koeffler HP
Oncotarget; 2015 Jan; 6(2):814-24. PubMed ID: 25528770
[TBL] [Abstract][Full Text] [Related]
20. Relationship between epidermal growth factor receptor gene mutations and the severity of adverse events by gefitinib in patients with advanced non-small cell lung cancer.
Fujiwara Y; Kiura K; Toyooka S; Takigawa N; Tokumo M; Hotta K; Aoe M; Tabata M; Matsuo K; Date H; Tanimoto M
Lung Cancer; 2006 Apr; 52(1):99-103. PubMed ID: 16503086
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]